Landscape Capital Management L.L.C. grew its position in shares of Shire PLC (NASDAQ:SHPG) by 68.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,695 shares of the biopharmaceutical company’s stock after purchasing an additional 2,720 shares during the period. Landscape Capital Management L.L.C.’s holdings in Shire were worth $1,039,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI grew its position in shares of Shire by 22.1% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 375 shares in the last quarter. Pitcairn Co. lifted its stake in Shire by 26.5% in the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 401 shares during the last quarter. Thompson Investment Management Inc. lifted its stake in Shire by 5.2% in the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock valued at $1,438,000 after buying an additional 468 shares during the last quarter. ETRADE Capital Management LLC lifted its stake in Shire by 8.5% in the third quarter. ETRADE Capital Management LLC now owns 6,746 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 528 shares during the last quarter. Finally, Hills Bank & Trust Co. raised its stake in shares of Shire by 12.2% during the fourth quarter. Hills Bank & Trust Co. now owns 5,960 shares of the biopharmaceutical company’s stock valued at $924,000 after purchasing an additional 647 shares in the last quarter. Institutional investors and hedge funds own 19.75% of the company’s stock.
Several brokerages have commented on SHPG. Piper Jaffray Companies reiterated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Liberum Capital reaffirmed a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. Cowen set a $225.00 target price on Shire and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research lowered Shire from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $204.00.
Shire PLC (NASDAQ:SHPG) traded up $1.34 during midday trading on Wednesday, hitting $132.56. The stock had a trading volume of 522,875 shares, compared to its average volume of 1,270,000. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.55 and a current ratio of 0.97. The firm has a market capitalization of $40,130.00, a price-to-earnings ratio of 21.84, a P/E/G ratio of 0.77 and a beta of 1.43. Shire PLC has a 52 week low of $123.73 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.86 by $0.12. The business had revenue of $4.14 billion during the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.37 earnings per share. analysts anticipate that Shire PLC will post 15.23 EPS for the current fiscal year.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be given a $0.8937 dividend. This represents a dividend yield of 1.33%. This is a boost from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s dividend payout ratio (DPR) is presently 17.30%.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.